{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"groups":[{"description":"Participants diagnosed with MM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days.","id":"OG000","title":"Multiple Myeloma (MM)"},{"description":"Participants diagnosed with WM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days.","id":"OG001","title":"Waldenstrom's Macroglobulinemia (WM)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least one dose of the study drug.","reportingStatus":"POSTED","timeFrame":"Study treatment discontinuation up to 30 days post study treatment discontinuation","title":"Number of Participants Who Died Due to Progressive Disease During the 30 Days Following Discontinuation From Study Treatment","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}